Division of Pulmonary, Allergy
and Critical Care Medicine
|
Address:
|
Neil W. Schluger, M.D. Professor of Medicine, Epidemiology &
Environmental Health Sciences Chief, Division of Pulmonary, Allergy,
and Critical Care Medicine Clinical and Research
Interests Dr. Schluger’s
main area of academic interest has been in tuberculosis, including clinical
trials, molecular epidemiology, development and evaluation of diagnostics,
and human host immune responses. He is the principal investigator at More recently, in addition to
his studies in tuberculosis, he has led clinical trials for the use of retinoids in the treatment of emphysema and for the use
of interferon gamma in the treatment of idiopathic pulmonary fibrosis. Education and Training Harvard University, B.A.,
1981 Honors 1979-1980 John Harvard
Scholarship Publications (partial
list) 1. Sandman
L, Davidow A, Bonk S, Schluger NW.
Risk factors for rifampin mono-resistant
tuberculosis: a case control study. Am J Respir Crit Care Med, 1999; 159: 468-472. 2. Schluger
NW, Huberman R, Holzman R, Rom WN, Cohen DI. Screening for infection and
disease as a tuberculosis control measure among indigents in New York City,
1994-1997, Int J Tuberc
Lung Dis 1999; 3: 281-286 3. 4. Davidson
H, Schluger
NW, Feldman PH, Valentine DP, Telzak
EE, Laufer FN. The effects of increasing incentives
on adherence to tuberculosis directly observed therapy. Int
J Tuberc Lung Dis 2000;
9: 860-865 5. Raju B, Schluger NW. Significance of
respiratory isolates of Mycobacterium avium complex
in HIV-positive and HIV-negative patients. Int J
Infect Dis. 2000; 4:134-139. 6. Schluger
NW. The impact of drug resistance on the global tuberculosis epidemic. Int J Tuberc Lung Dis 2000; 4: S71-5 7. Schluger
NW. Clearing up confusion in pulmonary embolism
diagnosis. J Crit Illness 2000; 15: 592-598 8. Johnson
S, Brusasca P, Lyashchenko
K, Spencer JS, Wiker HG, Bifani
P, Shashkina E, Kreiswirth
B, Harboe M, Schluger N, Gomez M, Gennaro ML. Characterization of the secreted MPT53
antigen of Mycobacterium tuberculosis. Infect Immun.
2001; 69: 5936-9. 9. Schluger
NW. Recent advances in our understanding of human
host responses to tuberculosis. Respiratory Research 2001; 2: 157-163 10. Schluger
NW, Burzynski J.
Tuberculosis in HIV-infected patients: epidemiology, pathogenesis, treatment.
HIV Clinical Trials 2001; 2: 356-365 11. Schluger
NW. Changing Approaches to the Diagnosis of
Tuberculosis. Am J Respir Crit
Care Med.2001; 164: 2020-2024 12. Chan
ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and human host-defense against tuberculosis?
Current knowledge. Am J Respir Cell Mol Biol 2001; 25: 606-612. 13. Tuberculosis
Trials Consortium*. The Tuberculosis Trials Consortium: A
Model for Clinical Trials Collaborations. Public Health Reports 2001; 116
(Supplement 1):41-49. 14. N
Bock, T Sterling, CD Hamilton, C Pachucki, YC Wang,
DS Conwell, A Mosher, M Samuels, Vernon A, and the Tuberculosis Trials
Consortium*. A prospective, randomized, double-blind study of
the tolerability of rifapentine 600 mg, 900 mg and
1200 mg plus isoniazid in the continuation phase of
tuberculosis treatment. Amer J Resp
Crit Care Med 2002; 165: 1526-1530. 15. Schluger
NW. Challenges of Treating Latent Tuberculosis
Infection. Chest, 2002;121:1733-1735 16. Geng E, Kreiswirth B,
Driver C, Li J, Burzynski J, LaPaz
A, Della Latta P, Schluger NW. Changes in
tuberculosis transmission in New York City from 1990-1999: implications for
tuberculosis control and elimination practices. New Engl
J Med, 2002; 346: 1453-1458 17. Schluger
NW, Perez D, Liu YM. Reconstitution of immune
responses to tuberculosis in HIV-infected patients receiving anti-retroviral
therapy. Chest 2002; 122:597-602 18. Tuberculosis
Trials Consortium*. Treatment of drug-susceptible
tuberculosis with a once weekly regimen of isoniazid
and rifapentine in the continuation phase. The
Lancet 2002; 360: 528-534 |
© Columbia University,